Jun 2013 to 2000 Licensed Realtor/Sales AgentPepsiCo Canton, MA Sep 1999 to Jun 2013 Account Sales ManagerPepsi Cola Wilmington, MA Jun 1994 to Sep 1999 Bulk Service Merchandiser
Education:
University of Massachusetts/Lowell Lowell, MA 1992 to 1997 BA in Liberal Arts/History
Oct 2010 to 2000 Agency Services Associate SupervisorHanover Insurance Group Worcester, MA Mar 2009 to Sep 2010 Service Operations AssociateNorthwestern Mutual Financial Network Springfield, MA Jun 2006 to Jan 2008 Licensed Financial RepresentativeUDance Marathon Amherst, MA Jun 2007 to Nov 2007 Head of Marketing and Corporate Relations
Education:
University of Massachusetts Amherst, MA Jan 2004 to Jan 2008 Bachelor of Business Administration in Finance
Nov 2011 to 2000Vector Marketing Corporation Albany, NY Aug 2011 to Oct 2011 SalesmanConstruction/Labor worker side jobs/mow lawns Jul 2004 to Aug 2011Hoffman's Car Wash Albany, NY Apr 2011 to Jun 2011North Greenbush Youth Center Counselor Jan 2010 to May 2010Moscatello's Restaurant
Jan 2007 to Mar 2007
Education:
SUNY Albany Albany, NY Aug 2009 to 2000 EnglishHudson Valley Community College Troy, NY Jan 2006 to Aug 2009 Associates in ScienceBryant University Smithfield, RI Sep 2005 to Dec 2005LaSalle Institute Troy, NY Sep 2001 to May 2005 High School Diploma
Name / Title
Company / Classification
Phones & Addresses
Sean O'connell
SHINE-A-BLIND Blind Cleaning
Worcester, MA 01602 5087550555
Us Patents
Method For Controlling Viral Infections Through Adoptive Transfer Of A Cell Product Comprising An Expanded And Enriched Population Of Superactivated Cytokine Killer Cells
- Houston TX, US Lilit Garibyan - Newton MA, US Beverly W. Lubit - Kinnelon NJ, US Sean O'Connell - Budd Lake NJ, US
Assignee:
VERDURE BIOTECH, INC. - Houston TX
International Classification:
A61K 35/17 A61P 37/04
Abstract:
The invention of the present disclosure provides a method for treating a viral infection in a recipient subject suffering from or at risk of a viral infection including administering to the recipient subject a pharmaceutical composition comprising a therapeutic amount of superactivated cytokine killer T cells (SCKTCs) and a pharmaceutically acceptable carrier, and mobilizing an immune response of the recipient subject to the viral pathogen. When tested in vitro, the SCKTCs are characterized by a predominant production of T1 dominant cytokines including IFN-γ; an IFN-γ:IL-4 ratio of at least 500:1; and at least 50% killing of target A549 cells at an effector:target ratio of 20:1. The present disclosure further provides a method of preparing a pharmaceutical composition comprising an enriched population of superactivated cytokine killer T cells (SCKTCs) wherein pulsing steps with monocyte-derived dendritic cells (DCs) loaded with alpha-GalCer achieve at least an 80% pure population of SCKTCs without positive or negative cell separation methods.
Universal Vaccines Against Immunogens Of Pathogenic Organisms That Provide Organism-Specific And Cross-Group Protection
The present disclosure provides, in part, a priming and boosting vector-based platform to develop vaccines against viral pathogens that is tailored to elicit a broad T cell response targeting conserved viral epitopes while including helper T cell (T) epitopes and an adjuvant to achieve a balanced immune response consisting of both cellular immunity, coupled with a broad neutralizing antibody response in the design of a candidate universal vaccine to HIV or a human coronavirus, e.g., SARS-CoV-2. The universal vaccines are prepared against an immunogen of an infectious pathogenic virus comprising at least one nucleic acid polynucleotide comprising an open reading frame encoding at least one polypeptide antigen or an immunogenic fragment thereof, wherein the polypeptide antigen, or the immunogenic fragment thereof, comprises a conserved internal protein that is enriched in T cell recognition antigens. The effectiveness of the priming and boosting platform is tested in humanized mouse models: a transgenic mouse model that expresses the hACE2 gene under the control of the human cytokeratin 18 promoter and a humanized mouse model comprising a fully functional human immune system.